Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Amsterdam, Netherlands Clinical Trials

A listing of Amsterdam, Netherlands clinical trials actively recruiting patients volunteers.

RESULTS

Found (31) clinical trials

APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma

The study will consist of 2 phases, a Phase I/dose escalation phase and a Phase II/expansion phase. Patients with relapsed and relapsed or refractory multiple myeloma will be enrolled in both phases of the study. Eligible patients will undergo leukapheresis in order to harvest T cells, which is the starting …

Phase

0.0 miles

Learn More »

Efficacy of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium

The purpose of this study is to assess the efficacy and performance of the C2 Focal Cryoablation System in patients with BE. The study will involve up to 50 subjects with each subject receiving cryoablation therapy of all visible BE using the C2 System Focal Ablation System. Length of ablation …

Phase

0.0 miles

Learn More »

131I-IPA + XRT as Treatment for Patients With Glioblastoma Multiforme

Primary objective To assess the safety and tolerability of intravenous 131I-IPA administered concomitantly to 2nd line XRT in recurrent GBM Secondary objectives To assess the maximum tolerated dose (MTD) of 131I -IPA administered concomitantly to 2nd line XRT in recurrent GBM To evaluate the feasibility of a fractionated administration of …

Phase

0.24 miles

Learn More »

CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations

Treatment with immune modulating agents may result in long lasting anti-tumor responses in patients with cancer. However, only a subset of patients obtains durable remission. Treatment strategies that aim at recruiting tumor antagonizing cellular components of the immune system holds great promise. CyPep-1 is a chemically synthesized peptide with oncolytic …

Phase

0.24 miles

Learn More »

A Study to Evaluate the Safety Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease

This study is a multicenter, double blind, randomized, placebo-controlled study to evaluate the safety, tolerability and immunogenicity of different doses, regimens and combinations of Tau targeted vaccines in participants with early Alzheimer's Disease.

Phase

0.24 miles

Learn More »

Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer

Rationale: Currently, third line systemic treatment for patients with advanced, wild type K-RAS and as has recently been demonstrated with wild type N-RAS (thereafter referred to as wild type RAS) colorectal cancer (CRC) includes epidermal growth factor receptor (EGFR) inhibition with the anti-EGFR antibody cetuximab. This type of treatment has …

Phase

0.28 miles

Learn More »

GEN3013 (DuoBody -CD3xCD20) Safety Trial in Patients With Relapsed Progressive or Refractory B-Cell Lymphoma

The trial is an open-label, multi-center safety trial of GEN3013 (DuoBody-CD3xCD20). The trial consists of two parts: a dose escalation part (phase 1, first-in-human (FIH) and an expansion part phase 2a). The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been determined.

Phase

0.39 miles

Learn More »

A Study to Determine Dose Safety Tolerability and Efficacy of CC-220 Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma

Subjects assigned to CC-220 monotherapy, who develop progressive disease (PD) will have the option to receive DEX in addition to CC-220 after consultation with the Medical Monitor. The dose of CC-220 will not be higher than the dose of CC-220 used in combination with dexamethasone in Cohort B that has …

Phase

2.84 miles

Learn More »

A Study of Isatuximab-based Therapy in Participants With Lymphoma

The total study duration per patient is up to 28 months, including an up to 28-day screening period, an up to 96-week treatment period, and a 90-day safety follow up period.

Phase

2.84 miles

Learn More »

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients

The purpose of this study is to investigate the safety, pharmacokinetics and preliminary efficacy of combinations treatment of ruxolitinib with 3 novel compounds: siremadlin, crizanlizumab and MBG453 in myelofibrosis (MF) subjects.

Phase

2.84 miles

Learn More »